184 related articles for article (PubMed ID: 30724380)
1. Enhanced antitumour activity of doxorubicin and simvastatin combination loaded nanoemulsion treatment against a Swiss albino mouse model of Ehrlich ascites carcinoma.
Alkreathy HM; Alkhatib MH; Al Musaddi SA; Balamash KSA; Osman NN; Ahmad A
Clin Exp Pharmacol Physiol; 2019 May; 46(5):496-505. PubMed ID: 30724380
[TBL] [Abstract][Full Text] [Related]
2. QbD-based development of α-linolenic acid potentiated nanoemulsion for targeted delivery of doxorubicin in DMBA-induced mammary gland carcinoma: in vitro and in vivo evaluation.
Tripathi CB; Parashar P; Arya M; Singh M; Kanoujia J; Kaithwas G; Saraf SA
Drug Deliv Transl Res; 2018 Oct; 8(5):1313-1334. PubMed ID: 29748834
[TBL] [Abstract][Full Text] [Related]
3.
Alkhatib MH; Alshehri WS; Abdu FB
J Pharm Bioallied Sci; 2018; 10(1):35-42. PubMed ID: 29657506
[TBL] [Abstract][Full Text] [Related]
4. The activity against Ehrlich's ascites tumors of doxorubicin contained in self assembled, cell receptor targeted nanoparticle with simultaneous oral delivery of the green tea polyphenol epigallocatechin-3-gallate.
Ray L; Kumar P; Gupta KC
Biomaterials; 2013 Apr; 34(12):3064-76. PubMed ID: 23357370
[TBL] [Abstract][Full Text] [Related]
5. Sclareol is a potent enhancer of doxorubicin: Evaluation of the free combination and co-loaded nanostructured lipid carriers against breast cancer.
Borges GSM; Silva JO; Fernandes RS; de Souza ÂM; Cassali GD; Yoshida MI; Leite EA; de Barros ALB; Ferreira LAM
Life Sci; 2019 Sep; 232():116678. PubMed ID: 31344429
[TBL] [Abstract][Full Text] [Related]
6. The synergistic effect between vanillin and doxorubicin in ehrlich ascites carcinoma solid tumor and MCF-7 human breast cancer cell line.
Elsherbiny NM; Younis NN; Shaheen MA; Elseweidy MM
Pathol Res Pract; 2016 Sep; 212(9):767-77. PubMed ID: 27493101
[TBL] [Abstract][Full Text] [Related]
7. The antitumor effects of tetrodotoxin and/or doxorubicin on Ehrlich ascites carcinoma-bearing female mice.
El-Dayem SM; Fouda FM; Ali EH; Motelp BA
Toxicol Ind Health; 2013 Jun; 29(5):404-17. PubMed ID: 22317827
[TBL] [Abstract][Full Text] [Related]
8. Simvastatin Coadministration Modulates the Electrostatically Driven Incorporation of Doxorubicin into Model Lipid and Cell Membranes.
Bartkowiak A; Nazaruk E; Gajda E; Godlewska M; Gaweł D; Jabłonowska E; Bilewicz R
ACS Biomater Sci Eng; 2022 Oct; 8(10):4354-4364. PubMed ID: 36173110
[TBL] [Abstract][Full Text] [Related]
9. Effect of Cremophor EL on the pharmacokinetics, antitumor activity and toxicity of doxorubicin in mice.
Badary OA; Al-Shabanah OA; Al-Gharably NM; Elmazar MM
Anticancer Drugs; 1998 Oct; 9(9):809-15. PubMed ID: 9840728
[TBL] [Abstract][Full Text] [Related]
10. Enhanced anticancer effect and reduced toxicity of doxorubicin in combination with thymoquinone released from poly-N-acetyl glucosamine nanomatrix in mice bearing solid Ehrlish carcinoma.
El-Ashmawy NE; Khedr EG; Ebeid EM; Salem ML; Zidan AA; Mosalam EM
Eur J Pharm Sci; 2017 Nov; 109():525-532. PubMed ID: 28890201
[TBL] [Abstract][Full Text] [Related]
11. Iron N-(2-hydroxy acetophenone) glycinate (FeNG), a non-toxic glutathione depletor circumvents doxorubicin resistance in Ehrlich ascites carcinoma cells in vivo.
Ganguly A; Chakraborty P; Banerjee K; Chatterjee S; Basu S; Sarkar A; Chatterjee M; Choudhuri SK
Biometals; 2012 Feb; 25(1):149-63. PubMed ID: 21915630
[TBL] [Abstract][Full Text] [Related]
12. Self-assembled oligopeptide nanostructures for co-delivery of drug and gene with synergistic therapeutic effect.
Wiradharma N; Tong YW; Yang YY
Biomaterials; 2009 Jun; 30(17):3100-9. PubMed ID: 19342093
[TBL] [Abstract][Full Text] [Related]
13. The in vivo behavior and antitumor activity of doxorubicin-loaded poly(γ-benzyl l-glutamate)-block-hyaluronan polymersomes in Ehrlich ascites tumor-bearing BalB/c mice.
Upadhyay KK; Mishra AK; Chuttani K; Kaul A; Schatz C; Le Meins JF; Misra A; Lecommandoux S
Nanomedicine; 2012 Jan; 8(1):71-80. PubMed ID: 21703363
[TBL] [Abstract][Full Text] [Related]
14. A liposomal formulation of simvastatin and doxorubicin for improved cardioprotective and anti-cancer effect.
Bjørnstad R; Reiten IN; Knudsen KS; Schjøtt J; Herfindal L
Int J Pharm; 2022 Dec; 629():122379. PubMed ID: 36370997
[TBL] [Abstract][Full Text] [Related]
15. Effects of L-histidinol on the antitumour activity and acute cardiotoxicity of doxorubicin in mice.
Al-Shabanah OA; Badary OA; Al-Gharably NM; Al-Sawaf HA
Pharmacol Res; 1998 Sep; 38(3):225-30. PubMed ID: 9782074
[TBL] [Abstract][Full Text] [Related]
16. Curcumin loaded selenium nanoparticles synergize the anticancer potential of doxorubicin contained in self-assembled, cell receptor targeted nanoparticles.
Kumari M; Purohit MP; Patnaik S; Shukla Y; Kumar P; Gupta KC
Eur J Pharm Biopharm; 2018 Sep; 130():185-199. PubMed ID: 29969665
[TBL] [Abstract][Full Text] [Related]
17. The role of a novel copper complex in overcoming doxorubicin resistance in Ehrlich ascites carcinoma cells in vivo.
Majumder S; Dutta P; Mookerjee A; Choudhuri SK
Chem Biol Interact; 2006 Feb; 159(2):90-103. PubMed ID: 16289015
[TBL] [Abstract][Full Text] [Related]
18. Antitumor Properties of Modified Detonation Nanodiamonds and Sorbed Doxorubicin on the Model of Ehrlich Ascites Carcinoma.
Medvedeva NN; Zhukov EL; Inzhevatkin EV; Bezzabotnov VE
Bull Exp Biol Med; 2016 Jan; 160(3):372-5. PubMed ID: 26742746
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of Combination Therapy with Linalool and Doxorubicin Encapsulated by Liposomes as a Two-in-One Hybrid Carrier System for Epithelial Ovarian Carcinoma.
Wi TI; Won JE; Lee CM; Lee JW; Kang TH; Shin BC; Han HD; Park YM
Int J Nanomedicine; 2020; 15():8427-8436. PubMed ID: 33149585
[TBL] [Abstract][Full Text] [Related]
20. Development and characterization of hyaluronic acid-anchored PLGA nanoparticulate carriers of doxorubicin.
Yadav AK; Mishra P; Mishra AK; Mishra P; Jain S; Agrawal GP
Nanomedicine; 2007 Dec; 3(4):246-57. PubMed ID: 18068091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
